

**Minutes of the September 11, 2009
Pharmacy & Therapeutics (P&T) Committee Meeting
SD Department of Social Services, Medical Services Division**

Members present

Dana Darger, R.Ph.; Verdayne Brandenburg, M.D.; Bill Ladwig, R.Ph.; Dennis Hedge, PharmD.; Rick Holm, M.D.; Debra Farver, PharmD.; Willis Sutliff, M.D.; Galen Goeden, R.Ph.

Members absent

Timothy Soundy, M.D., James Engelbrecht, M.D.

DSS staff present

Mike Jockheck, R.Ph.; Revi Warne, DSS

HID staff present

Candace Rieth, Pharm.D.

Administrative Business

The P&T meeting was called to order by D. Darger at approximately 1:00pm. The minutes of the June 12, 2009 meeting were presented. V. Brandenburg made a motion to approve with one correction; T. Soundy should be listed as absent from the June meeting. B. Ladwig seconded the motion. The motion was approved unanimously.

Prior Authorization Statistics

C. Rieth presented an overview of the prior authorization (PA) activity for June 2009. There were a total of 1,582 PAs processed in the month of June, with 99.43% of those requests responded to in less than 8 hours. There were 1,347 (85%) requests received electronically and 235 (15%) requests received by fax. In response to a request from the committee, C. Rieth presented the number of approvals and denials, by form type, for the faxed (manual) PA requests.

Analysis of the Top 15 Therapeutic Classes

C. Rieth reviewed the Top 15 Therapeutic Classes by total cost of claims from 04/01/2009 – 06/30/2009. The top five classes were antipsychotics, anticonvulsants, cerebral stimulants, amphetamines, and beta-adrenergic agonists. The top 15 therapeutic classes make up 41.66% of total claims. D. Darger discussed the proton pump inhibitors cost per prescription. The committee suggested a tier process be considered. This will be an agenda item for the December meeting.

Antipsychotic/Antidepressant/Xopenex Mailing

M. Jockheck gave an update on the mailings. The antidepressant, antipsychotic, and Xopenex mailings are in the final approval stages. The committee will be notified when these letters are mailed. W. Sutliff made a motion that the psych experts on the committee develop a proposal for a tiered system for the antipsychotics and the antidepressants and present it at the December meeting. This proposal should also take into consideration the committee's concern with polypharmacy. D. Farver seconded the motion. The motion was approved unanimously.

Targeted Immunomodulators Review

C. Rieth reviewed targeted immunomodulators with the P&T committee. A prior authorization was placed on this class of medications at the June meeting. Prior authorization criteria were developed for the committee to review. M. Jockheck also reported on the medical claims utilization of these agents. There was no public

comment. B. Ladwig made a motion to approve the criteria presented. R. Holm seconded the motion. The motion was approved unanimously.

Uloric Review

C. Rieth reviewed Uloric with the P&T committee. A prior authorization was placed on Uloric at the June meeting. Prior authorization criteria were developed for the committee to review. There was no public comment. A suggestion was made to include 'other' as a checkbox. B. Ladwig made a motion to approve the criteria presented with the additional check box. R. Holm seconded the motion. The motion was approved unanimously.

Azor/Exforge Review

C. Rieth reviewed Azor/Exforge information with the P&T committee. There was no public comment. B. Ladwig made a motion to include Azor and Exforge with the ARB prior authorization already in place and to grandfather current patients taking these agents. W. Sutliff seconded the motion. The motion was approved unanimously.

Solodyn/Oracea Review

C. Rieth reviewed Solodyn/Oracea information with the P&T committee. There was no public comment. W. Sutliff made a motion to place Solodyn and Oracea on prior authorization immediately. B. Ladwig seconded the motion. The motion was approved unanimously.

CaloMist/Nascobal Review

C. Rieth reviewed CaloMist/Nascobal information with the P&T committee. There was no public comment. G. Goeden made a motion to place these agents on prior authorization. B. Ladwig seconded the motion. The motion was approved unanimously.

Nuvigil Review

C. Rieth reviewed Nuvigil information with the P&T committee. There was no public comment. G. Goeden made a motion to place Provigil and Nuvigil on prior authorization. W. Sutliff seconded the motion. The motion was approved unanimously. Because Provigil was not on the September agenda, this topic will be discussed at the December meeting.

Nucynta

C. Rieth reviewed Nucynta information with the P&T committee. J. Stoffel spoke on behalf of Ortho McNeil Janssen, manufacturer of Nucynta. Because V. Brandenburg is doing research with Nucynta, he recused himself from the discussion. W. Sutliff made a motion to place Nucynta on prior authorization. R. Holm seconded the motion. The committee suggested that Nucynta be used second line for opioid naïve patients, following failure with other immediate release schedule-II opioids. The motion was approved unanimously.

The next meeting date is December 11, 2009. The location should remain the same. W. Sutliff asked that psychostimulants be added to the December agenda. A motion was made by G. Goeden at 2:15pm to adjourn the SD Medicaid P&T meeting. B. Ladwig seconded. Motion passed unanimously and the meeting was adjourned.